| Membrane transporters in drug development KM Giacomini, SM Huang, DJ Tweedie, LZ Benet, KLR Brouwer, X Chu, ... Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3481* | 2010 |
| Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH‐dependent solubility the Achilles heel of targeted therapy? NR Budha, A Frymoyer, GS Smelick, JY Jin, MR Yago, MJ Dresser, ... Clinical Pharmacology & Therapeutics 92 (2), 203-213, 2012 | 346 | 2012 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 311 | 2015 |
| Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug KS Fenner, MD Troutman, S Kempshall, JA Cook, JA Ware, DA Smith, ... Clinical Pharmacology & Therapeutics 85 (2), 173-181, 2008 | 304 | 2008 |
| Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152) JA Flygare, M Beresini, N Budha, H Chan, IT Chan, S Cheeti, F Cohen, ... Journal of medicinal chemistry 55 (9), 4101-4113, 2012 | 266 | 2012 |
| Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse H Zaher, AA Khan, J Palandra, TG Brayman, L Yu, JA Ware Molecular pharmaceutics 3 (1), 55-61, 2006 | 200 | 2006 |
| Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans Y Yamasaki, I Ieiri, H Kusuhara, T Sasaki, M Kimura, H Tabuchi, Y Ando, ... Clinical Pharmacology & Therapeutics 84 (1), 95-103, 2008 | 183 | 2008 |
| Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development GS Smelick, TP Heffron, L Chu, B Dean, DA West, SL DuVall, BL Lum, ... Molecular pharmaceutics 10 (11), 4055-4062, 2013 | 175 | 2013 |
| Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice S Shukla, H Zaher, A Hartz, B Bauer, JA Ware, SV Ambudkar Pharmaceutical research 26, 480-487, 2009 | 168 | 2009 |
| Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe BL Urquhart, JA Ware, RG Tirona, RH Ho, BF Leake, UI Schwarz, H Zaher, ... Pharmacogenetics and genomics 18 (5), 439-448, 2008 | 154 | 2008 |
| Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors D Juric, I Krop, RK Ramanathan, TR Wilson, JA Ware, ... Cancer discovery 7 (7), 704-715, 2017 | 145 | 2017 |
| Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction … CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ... Drug metabolism and disposition 43 (4), 490-509, 2015 | 145 | 2015 |
| Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin H Zaher, HEM zu Schwabedissen, RG Tirona, ML Cox, LA Obert, ... Molecular pharmacology 74 (2), 320-329, 2008 | 139 | 2008 |
| Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors SO Dolly, AJ Wagner, JC Bendell, HL Kindler, LM Krug, TY Seiwert, ... Clinical Cancer Research 22 (12), 2874-2884, 2016 | 130 | 2016 |
| Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with … T Powles, MR Lackner, S Oudard, B Escudier, C Ralph, JE Brown, ... Journal of Clinical Oncology 34 (14), 1660, 2016 | 116 | 2016 |
| Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile MP Grillo, CG Knutson, PE Sanders, DJ Waldon, F Hua, JA Ware Drug metabolism and disposition 31 (11), 1327-1336, 2003 | 109 | 2003 |
| Disease‐associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the International Transporter Consortium R Evers, M Piquette‐Miller, JW Polli, FGM Russel, JA Sprowl, K Tohyama, ... Clinical Pharmacology & Therapeutics 104 (5), 900-915, 2018 | 104 | 2018 |
| Expression and function of ABCB1 and ABCG2 in human placental tissue D Kolwankar, DD Glover, JA Ware, TS Tracy Drug metabolism and disposition 33 (4), 524-529, 2005 | 100 | 2005 |
| Bridging the gap between preclinical and clinical studies using pharmacokinetic–pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor H Wong, L Vernillet, A Peterson, JA Ware, L Lee, JF Martini, P Yu, C Li, ... Clinical Cancer Research 18 (11), 3090-3099, 2012 | 96 | 2012 |
| Mechanistic Studies on the Bioactivation of Diclofenac: Identification of Diclofenac-S-acyl-glutathione in Vitro in Incubations with Rat and Human Hepatocytes MP Grillo, F Hua, CG Knutson, JA Ware, C Li Chemical research in toxicology 16 (11), 1410-1417, 2003 | 95 | 2003 |
